Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data

Figure 5 The Kaplan-Meier plot for 10-year disease-free survival in patients with stage I/II hepatocellular carcinoma with or without copy number aberrations involving MYC, WRN, ELAC2, GAK, SYK, or MECOM using The Cancer Genome Atlas Liver Hepatocellular Carcinoma data. A: Patients with stage I hepatocellular carcinoma (HCC) (n = 108) with any copy number aberrations (CNAs) affecting one of the six genes identified in this study (MYC, WRN, ELAC2, GAK, SYK, or MECOM) had a trend for worse outcome after resection (dashed line, P = 0.0583). B: Asian patients with stage I HCC (n = 73) and CNAs affecting these six genes (dashed line) exhibited poorer outcome compared to those cases without such CNAs (solid line, P = 0.0203). C: Patients with stage I/IIHCC (n = 155), and D: Asian patients with stage I/II HCC (n = 93) with/without any of these CNAs affecting MYC, WRN, ELAC2, GAK, SYK, or MECOM showed no change in DFS (P = 0.2552 and P= 0.1707, respectively). DFS: Disease-free survival.